KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Free Cash Flow (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Free Cash Flow data on record, last reported at $77.9 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 176.98% year-over-year to $77.9 million; the TTM value through Dec 2025 reached $169.0 million, up 372.07%, while the annual FY2025 figure was $169.0 million, 372.07% up from the prior year.
  • Free Cash Flow reached $77.9 million in Q4 2025 per EBS's latest filing, up from $2.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $328.7 million in Q4 2021 and bottomed at -$199.1 million in Q1 2023.
  • Average Free Cash Flow over 5 years is $10.2 million, with a median of $5.9 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: crashed 1250.54% in 2023, then soared 509.09% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $328.7 million in 2021, then tumbled by 46.58% to $175.6 million in 2022, then tumbled by 88.21% to $20.7 million in 2023, then plummeted by 588.89% to -$101.2 million in 2024, then soared by 176.98% to $77.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $77.9 million in Q4 2025, $2.4 million in Q3 2025, and $101.4 million in Q2 2025.